AG
CYCN icon

Advisor Group’s Cyclerion Therapeutics CYCN Stock Holding History

Advisor Group’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1
Closed – – 5291
2019
Q2 		$0 Buy
+1
New +$283 ﹤0.01% 5248

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Advisor Group's CYCN Position: Q3 2019 in Review

Advisor Group sold out of Cyclerion Therapeutics (CYCN) in Q3 2019, closing a stake of 1 share.

Advisor Group first reported a position in CYCN in Q2 2019 and held it in 1 quarter. The position peaked at $0 in Q2 2019. 90 funds tracked by Wall St. Rank hold CYCN as of Q3 2019.

  • Advisor Group reported no remaining Cyclerion Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Advisor Group sold 1 Cyclerion Therapeutics share in Q3 2019.
  • Advisor Group first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 1 quarter.
  • Advisor Group's Cyclerion Therapeutics position peaked at $0 in Q2 2019.
  • 90 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2019.

Based on Advisor Group's 13F filing for Q3 2019, filed 13 Nov 2019.